

A1
Could be
A1
(Amended) A composition comprising the polypeptide of Claim 1 and a pharmaceutically acceptable formulation agent.

A2 11. (Amended) The polypeptide of Claim 1 which is covalently modified with a water-soluble polymer.

In the specification:

Please amend the paragraphs at page 6, lines 9-17 as follows:

A3
Supp 1
Figure 1 illustrates the body weight of VGF knockout mice following administration of VGF-1a (SEQ ID NO: 2). The administration of VGF-1a was ceased at day 5 (as indicated by the arrow);

Figure 2 illustrates the antibody titer levels of a rabbit injected with VGF-1 (SEQ ID NO:1), calculated at 1:100 to 2x serial dilution;

Figure 3 illustrates the antibody titer levels of a rabbit injected with VGF-2 (SEQ ID NO:4), calculated at 1:100 to 2x serial dilution.

Please amend the paragraph at page 80, line 27 to page 81, line 2 as follows:

A4
Figure 1 illustrates the body weight of VGF knockout mice following administration of VGF-1a. Three of the four treated mice gained 10-15 percent in body weight. From this experiment, it was not possible to determine whether the increase in weight was a result of an increased uptake of food or water.

REMARKS

The Examiner indicated that claims 1-21 were pending at the issuance of the instant Office Action. Claims 1, 6-8, and 11 have been amended. Claims 2-5, 10, and 14-21 have been canceled. The amendments to the claims are fully supported by the specification. No new matter has been added as a result of the above-described amendments. The rejections set forth in the Office Action have been overcome by